Table 1 Patient demographics and clinical characteristics of the two groups of COVID-19 patients
Parameter Non-progressive group (n = 7) Progressive group (n = 20) p
Age 41 (29–65) 57 (23–81) 0.653
Sex 0.662
 Male 4 (57.1%) 8 (40%)
 Female 3 (42.8%) 12 (60%)
Comorbidities 3 (42.8%) 11(55%)
 Hypertension 1 (14.3%) 9 (45%) 0.204
 Diabetes mellitus 3 (42.9%) 2 (10%) 0.091
 Chronic renal failure 0 (0) 1 (5%) 1.000
 Malignancy 1 (14.3%) 1 (5%) 0.459
Treatment
 Hydorxychloroquine 6 (85.7%) 18 (90%) 1.000
 Azithromycin ± or other antibiotics 4 (57.1%) 11 (55%) 1.000
 Oseltamivir 3 (42.9%) 7 (35%) 1.000
 Favipiravir 1 (14.3%) 9 (45%) 0.204
 LMWH 0 (0) 6 (30%) 0.155
Length of hospital stay (day) 5 (0–17) 12.5 (0–29) 0.035
ICU admission 0 (0) 6 (30%) 0.155
Survival 1.000
 Dead 0 (0) 1 (5%)
 Alive 7 (100%) 19 (95%)
Data are n (%) or median (minimum–maximum)
ICU intensive care unit, LMWH low-molecular-weight heparin